14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AMOD vs SLXN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Silexion Therapeutics Corp (SLXN) captures the overall head-to-head institutional edge over Alpha Modus Holdings, Inc. (AMOD) on higher Unified Composite conviction (24.1/100 STRONG SELL vs. 45.4/100 HOLD) after splitting the core matrix 2–4 (led by Balance Sheet & Cash Flow), while AMOD wins 3–1 across the 6-pillar growth and valuation breakdown. AMOD trades at $0.84 (N/M Forward P/E, -127536.2% operating margin) versus SLXN at $1.76 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While AMOD currently prints a higher short-term Unified Composite Score (45.4/100 HOLD vs. SLXN 24.1/100 STRONG SELL), SLXN captures the overall institutional head-to-head verdict (2–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -127536.2% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: AMOD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.8); meanwhile SLXN is in a Breakdown options structure phase (RSI 66.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AMOD vs SLXN. Trailing 12-month operating profitability (AMOD -127536.2% vs SLXN 0.0%) and valuation multiples (AMOD N/M vs SLXN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.7M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AMOD vs SLXN Key Questions & Quantitative Answers
As of Nov 16, 2026, Silexion Therapeutics Corp (SLXN) captures the overall head-to-head institutional edge over Alpha Modus Holdings, Inc. (AMOD) on higher Unified Composite conviction (24.1/100 STRONG SELL vs. 45.4/100 HOLD) after splitting the core matrix 2–4 (led by Balance Sheet & Cash Flow), while AMOD wins 3–1 across the 6-pillar growth and valuation breakdown. AMOD trades at $0.84 (N/M Forward P/E, -127536.2% operating margin) versus SLXN at $1.76 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AMOD currently prints a higher short-term Unified Composite Score (45.4/100 HOLD vs. SLXN 24.1/100 STRONG SELL), SLXN captures the overall institutional head-to-head verdict (2–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -127536.2% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: AMOD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.8); meanwhile SLXN is in a Breakdown options structure phase (RSI 66.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AMOD leads the Growth & Scale pillar: AMOD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $7,138 TTM revenue (100.0% gross margin, -127536.2% operating margin), compared with SLXN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AMOD generates $7,138 in USD-normalized revenue versus N/A for SLXN. In operating R&D and SG&A reinvestment, AMOD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SLXN.
AMOD and SLXN trade at balanced relative valuation multiples. AMOD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SLXN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMOD (0.0% ROE) versus SLXN (-897.5% ROE) capital efficiency.
In options market volatility and institutional positioning, AMOD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (51.09β · 120% Vol realized risk). By comparison, SLXN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (28.94β · 9931% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.